Bayer has become a case for the patient investor Bayer has become a case for the patient investor Bayer has become a case for the patient investor

Bayer has become a case for the patient investor

Equities 4 minutes to read
Peter Garnry

Head of Saxo Strats

Summary:  Bayer shares plunged 18% yesterday as the German conglomerate was hit by a double whammy. On Friday, a US courtroom verdict opened the door for litigation costs related to its famous weed killer product Roundup to extend beyond the USD 16bn already set aside. In addition, the pharma division had to terminate an important phase three trial which was seen as the lifeboat that could save Bayer's pharma division facing two patent expirations related to 40% of the pharma division revenue.


Double whammy hits Bayer

Bayer shares plunged 18% yesterday on two bad news. The nightmare related to the Monsanto acquisition five years ago continues to haunt Bayer as a late verdict on Friday on Monsanto’s famous product Roundup opened up more risks for Bayer. In a worst case scenario, Bayer might have to pay up in litigation more than the $16bn already set a side on the balance sheet.

To make matters worse for Bayer, the company has been forced to halt a primary study on an experimental drug as it was not efficient enough relative to the benchmarks set forth in the study. In the pharma division, pressures are also going to increase over time as two of the division’s high revenue generating drugs are facing a patent expiry.

Can Bayer find a way out of its troubles?

As a result of all the uncertainty Bayer’s share price is down 68% from its high back in 2015 and is trading at levels not seen since 2012. This backdrop is obviously difficult for shareholders in Bayer and the question is whether there is a path to a more positive future?

The Monsanto litigation costs might go beyond $16bn, but it is an one-off item and thus not the going concern of Bayer. The failed phase 3 study of the drug asundexian is a significant setback for the equity case, because analysts were modelling the value of the pharma division on this drug to offset the expected decline in revenue and profitability from the patent expiries explained above. With Bayer’s 2-year forward EV/EBITDA multiple hovering just above 6x the company is valued at a deep discount (~33%) to the overall equity market, so there is a natural low level of expectations making it an obvious value case, but one has to be clear about the catalysts. Another key thing, or risk if you will, is that the market value has declined to $33.5bn which is below the net debt of the balance sheet which is dangerous territory to walk for any company. So what is the case and outlook for investors in Bayer?

The next year is likely another transition year with dark clouds hanging over the business so investors should be patient. Bayer still has a top notch crops science unit although the unit is expected to face headwinds in 2024, and is still very profitable. Analysts expect FY23 revenue of €47.9bn and EBITDA of €10.8bn and EBITDA has hovered steadily around the €11-13.5bn for six years in a testimony to the low variance in its operations. The potential catalysts from here is a potential split of the group to unlock value like we have seen from Siemens and GE in recent years. The next capital markets day is on 5 March 2024 and will likely be the key event where such an announcement might be provided to the market.

Analysts expect the dividend to be reduced to €2.15 for the FY23 which on a forward basis equates to an expected dividend yield of 6.3%. If we assume that Bayer does not need to issue equity capital and assume that Bayer can track average economic growth rates over the next 10 years then the real rate return expectation is 6.3% + 2% so roughly 8.3% annualised real rate return. That is roughly a 3%-point positive spread to the over equity market reflecting the uncertainty and risks related to investing in Bayer, and the risk that dividends could decline further in the future.

While it is a challenging time for Bayer the company has shown its ability to grow over many decades and build business value. A long-term investor in Bayer is betting on the company to settle the Monsanto litigation once and for all, maybe separating the businesses, and crops protection prices to stabilize and rise in the future. It will all require a lot of patience.

Bayer share price | Source: Saxo
Disclaimer

The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/legal/disclaimer/saxo-disclaimer)
- Full disclaimer (https://www.home.saxo/en-mena/legal/disclaimer/saxo-disclaimer)


Boulevard Plaza, Tower 1, 30th floor, office 3002
Downtown, P.O. Box 33641 Dubai, UAE

Contact Saxo

Select region

UAE
UAE

Trade responsibly
All trading carries risk. Read more. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more

Saxo Bank A/S is licensed by the Danish Financial Supervisory Authority and operates in the UAE under a representative office license issued by the Central bank of the UAE.

The content and material made available on this website and the linked sites are provided by Saxo Bank A/S. It is the sole responsibility of the recipient to ascertain the terms of and comply with any local laws or regulation to which they are subject.

The UAE Representative Office of Saxo Bank A/S markets the Saxo Bank A/S trading platform and the products offered by Saxo Bank A/S.